Supplemental Materials

Molecular Biology of the Cell

Braunstein et al.

Supplemental Figure 1



Figure S1. Cells expressing VCAM-1 were treated with CAM741 and velcade as described in Figure 1. AIRAPL IP was performed and purified precipitant was incubated *in-vitro* in the presence or absence of the de-ubiquitinating enzyme Usp2. IP content of AIRAPL, p97 and VCAM-1 was revealed by the indicated immunoblots.



Figure S2. Left-The effect of Bag6 mutant expression on proteasomal activity was evaluated by monitoring the steady state levels of ATF4 under the various conditions. PSMA1 proteaomal content serves as a loading control. Right- *In-vitro* evaluation of proteasome peptide hydrolysis activity was evaluated using Succinyl-LLVY-AMC.



Figure S3. Upon CAM741 and velcade treatment of cellsthe localization of p97 and AIRAPL and their interaction with VCAM-1 was revealed by cellular fractionation to cytosolic (S) and microsomal (P) fractions (as described in Figure 4B). Each fraction was immunopercipitated for VCAM-1. p97 and AIRAPL association was revealed by immunoblot.

Supplemental Figure 4



Figure S4. Cells expressing Insulin R6C with shRNA control or Bag6shRNA were evaluated 72hr post transfection for their Bag6, p97 and Insulin content by immunoblot.Where indicated velcade was added to the last 6hr prior to lysis.